DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Side Effect Reports to FDA

 
 



Index of reports > All Cases (2254)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine all cases. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 2254   Next >>

Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (4 standard cycles)

Cyclophosphamide
    Dosage: 650 mg/m2, day 1 (4 standard cycles)

Cyclophosphamide
    Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, day 1 (4 standard cycles)

Doxorubicin HCL
    Dosage: 35 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 100 mg/m2, day 1-3 (4 standard cycles)

Etoposide
    Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
    Administration route: Oral

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
    Administration route: Oral

Vincristine
    Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, day 8 (4 standard cycles)



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-27

Patient: male

Reactions: Dystonia, Encephalopathy, Parkinsonism

Drug(s) suspected as cause:
Cisplatin

Cyclophosphamide

Etoposide

Ifosfamide

Vincristine



Possible Vincristine side effects in 47 year old male

Reported by a physician from France on 2012-08-27

Patient: 47 year old male

Reactions: Respiratory Tract Infection Bacterial, Epstein-Barr Virus Associated Lymphoma, Congestive Cardiomyopathy, Systolic Dysfunction

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-06-08

Doxorubicin HCL
    Start date: 2012-06-11
    End date: 2012-07-10

Mabthera
    Start date: 2012-06-11

Nexium
    Administration route: Oral

Prednisolone
    Administration route: Oral
    Start date: 2012-06-08

Vincristine
    Start date: 2012-06-08

Other drugs received by patient: Previscan; Methotrexate Sodium; Potassium Chloride; Kineret; Kineret; Kineret; Cacit D3; Aspirin; Prednisone TAB; Acetaminophen; Acetaminophen W / Codeine; Alendronate Sodium / Cholecalciferol



Possible Vincristine side effects in male

Reported by a physician from France on 2012-08-27

Patient: male

Reactions: Renal Failure Acute

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-21
    End date: 2012-05-23

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-21
    End date: 2012-05-21

Levoleucovorin Calcium
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-05-21
    End date: 2012-05-25

Mabthera
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-19
    End date: 2012-05-19

Methotrexate Disodium
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-20

Methotrexate Disodium
    Start date: 2012-05-25

Prednisone TAB
    Administration route: Oral
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-20
    End date: 2012-05-24

Vincristine
    Start date: 2012-05-25

Vincristine
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-05-20

Other drugs received by patient: Cytarabine; Calciparine; Ondansetron Hydrochloride; Allopurinol; Valaciclovir HCL; Nexium; Lyrica; Bactrim DS; Emend



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin Hydrochloride
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in 10 year old male

Reported by a physician from United States on 2012-08-27

Patient: 10 year old male, weighing 76.1 kg (167.4 pounds)

Reactions: Hypersensitivity, Hyperglycaemia, Peripheral Motor Neuropathy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-06-06

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-05-22

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-06-13

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-06-13

Other drugs received by patient: Radiation



Possible Vincristine side effects in 79 year old female

Reported by a physician from Germany on 2012-08-27

Patient: 79 year old female

Reactions: Sciatica, Lumbar Vertebral Fracture

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive

Doxorubicin Hydrochloride
    Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive

Mabthera
    Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive

Prednisone
    Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive

Vincristine
    Indication: non-Hodgkin's Lymphoma Unspecified Histology Aggressive



Possible Vincristine side effects in male

Reported by a physician from Netherlands on 2012-08-27

Patient: male, weighing 95.0 kg (209.0 pounds)

Reactions: Cranial Nerve Disorder

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: third maintenance cycle
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2010-09-06

Cyclophosphamide

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: third maintenance cycle
    Start date: 2010-09-06

Neupogen
    Indication: Diffuse Large B-Cell Lymphoma

Neupogen
    Dosage: third maintenance cycle
    Start date: 2010-09-07

Prednisone TAB
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: third maintenance cycle
    Administration route: Oral
    Start date: 2010-09-06

Rituximab
    Dosage: third maintenance cycle
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2010-09-06

Rituximab
    Start date: 2010-11-29
    End date: 2011-03-21

Vincristine
    Dosage: third maintenance cycle
    Start date: 2010-09-06

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in female

Reported by a physician from Switzerland on 2012-08-27

Patient: female, weighing 87.7 kg (192.9 pounds)

Reactions: Cholecystitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-11-11

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-11-11

Prednisolone
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-11-12

Rituximab
    Dosage: concentration 1/mg/ml
    Start date: 2011-11-11

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-11-11

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-11-11

Other drugs received by patient: Pantoprazole; Exforge HCT; Dipyrone INJ; Bisoprolol Fumarate; Domperidon; Bactrim DS; Acetaminophen; Metformin Hydrochloride



Possible Vincristine side effects in 43 year old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-27

Patient: 43 year old female

Reactions: Off Label Use, Blindness

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin Hydrochloride

Etoposide

Ifosfamide

Vincristine



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Vincristine side effects in male

Reported by a physician from Germany on 2012-08-24

Patient: male

Reactions: Febrile Neutropenia, Skin Infection, Neutropenia, Pneumonitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Doxorubicin Hydrochloride
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-06
    End date: 2012-04-20

Prednisolone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-21

Rituximab
    Dosage: 750 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-01
    End date: 2012-04-16

Vincristine
    Dosage: 2 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Other drugs received by patient: MST / 00036302 /; Novalgin / 00169801 /; Rulid; Pantoprazole; Paspertin / 00041902 /; Acyclovir; Electrolytes NOS W / Macrogol 3350; Dipyrone INJ; Metoclopramide; Acyclovir



Possible Vincristine side effects in 52 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24

Patient: 52 year old female

Reactions: Tumour Lysis Syndrome, Posterior Reversible Encephalopathy Syndrome, Insomnia, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Daunorubicin HCL
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Daunorubicin HCL
    Dosage: at 50% dosage

Dexamethasone
    Indication: Premedication

Methylprednisolone Sodium Succinate
    Indication: B Precursor Type Acute Leukaemia

Prednisone TAB
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Vincristine
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Other drugs received by patient: Ondansetron; Voriconazole; Morphine Sulfate; Morphine



Possible Vincristine side effects in female

Reported by a physician from Thailand on 2012-08-24

Patient: female, weighing 57.4 kg (126.3 pounds)

Reactions: Neutropenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Prednisone TAB
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-24

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Vincristine side effects in 51 year old male

Reported by a physician from Germany on 2012-08-24

Patient: 51 year old male

Reactions: Progressive Multifocal Leukoencephalopathy

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: HIV Infection

Doxorubicin HCL
    Indication: HIV Infection

Doxorubicin HCL
    Indication: non-Hodgkin's Lymphoma

Mabthera
    Indication: non-Hodgkin's Lymphoma

Mabthera
    Indication: HIV Infection

Prednisone
    Indication: HIV Infection

Prednisone TAB
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: HIV Infection

Vincristine
    Indication: non-Hodgkin's Lymphoma



Possible Vincristine side effects in female

Reported by a physician from Bulgaria on 2012-08-24

Patient: female, weighing 63.0 kg (138.6 pounds)

Reactions: Circulatory Collapse, Bone Marrow Failure

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-23
    End date: 2012-05-25

Dexamethasone
    Dosage: 40 milligram
    Start date: 2012-06-02
    End date: 2012-06-05

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-23
    End date: 2012-05-26

Dexamethasone
    Dosage: 20 milligram
    Start date: 2012-05-16
    End date: 2012-05-19

Doxorubicin Hydrochloride
    Dosage: 80 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-05-26

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-30
    End date: 2012-06-07

Vincristine
    Dosage: 2 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-06-02

Other drugs received by patient: Milgamma; Dopamine HCL; Nexium; Atropine; Sodium Carbonate; Lyrica; Uromithexane; Electrolyte Infusions; Sodium Bicarbonate; Probitor; Tevagrastim



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-23

Patient: male

Reactions: Dystonia, Encephalopathy, Parkinsonism

Drug(s) suspected as cause:
Cisplatin

Cyclophosphamide

Etoposide

Ifosfamide

Vincristine



Possible Vincristine side effects in male

Reported by a physician from Germany on 2012-08-23

Patient: male, weighing 85.0 kg (187.0 pounds)

Reactions: Ascites

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Chemotherapy

Diuretics

Mabthera
    Dosage: unk
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-07-28
    End date: 2012-07-28

Prednisone TAB
    Indication: Chemotherapy

Ramipril

Vincristine
    Indication: Chemotherapy

Other drugs received by patient: Torsemide; Allopurinol; Allopurinol; Pantoprazole; Pantoprazole; Potassium Chloride; Metoprolol Tartrate; Potassium Chloride; Ramipril; Hydrochlorothiazide



Possible Vincristine side effects in female

Reported by a pharmacist from United States on 2012-08-23

Patient: female, weighing 9.1 kg (20.0 pounds)

Reactions: Extravasation, Crying, Infusion Site Oedema

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine

Other drugs received by patient: Lactulose; Zofran; Lidocain / Prilocaine; Miralax; Maxitrol



Possible Vincristine side effects in

Reported by a physician from United States on 2012-08-23

Patient:

Reactions: White Blood Cell Count Decreased, Neutrophil Count Decreased, Hypokalaemia

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Cisplatin
    Dosage: 3.5 mg/kg/day over 6 hours on day 4
    Start date: 2012-07-27

Cisplatin
    Dosage: 3.5 mg/kg/day over 6 hours on day 4
    Indication: Medulloblastoma
    Start date: 2012-07-26
    End date: 2012-07-26

Cisplatin
    Dosage: 3.5 mg/kg/day over 6 hours on day 4
    Start date: 2012-07-02
    End date: 2012-07-02

Cyclophosphamide
    Dosage: 60 mg/kg/day over 1 hour on day 5 and 6
    Indication: Medulloblastoma
    Start date: 2012-07-27
    End date: 2012-07-28

Cyclophosphamide
    Dosage: 60 mg/kg/day over 1 hour on day 5 and 6
    Start date: 2012-07-03
    End date: 2012-07-04

Etoposide
    Dosage: 2.5 mg/kg/day on days 4,5 and 6
    Start date: 2012-07-02
    End date: 2012-07-04

Etoposide
    Dosage: 2.5 mg/kg/day on days 4,5 and 6
    Start date: 2012-07-29

Etoposide
    Dosage: 2.5 mg/kg/day on days 4,5 and 6
    Indication: Medulloblastoma
    Start date: 2012-07-26
    End date: 2012-07-28

Furosemide
    Dosage: 5 mg, qd
    Start date: 2012-07-28
    End date: 2012-07-29

Isotretinoin
    Dosage: 80 mg/m2/dose, bid on days 1-4
    Administration route: Oral
    Indication: Medulloblastoma
    Start date: 2012-07-23
    End date: 2012-07-27

Isotretinoin
    Dosage: 80 mg/m2/dose, bid on days 1-4
    Administration route: Oral
    Start date: 2012-06-29

Vincristine
    Dosage: 0.05 mg/kg/day on days 4 11 and 18
    Start date: 2012-07-02

Vincristine
    Dosage: 0.05 mg/kg/day on days 4 11 and 18
    Indication: Medulloblastoma
    Start date: 2012-07-23

Vincristine
    Dosage: 0.05 mg/kg/day on days 4 11 and 18
    Start date: 2012-07-27

Vorinostat
    Dosage: 230 mg/m2/dose on days 1-4
    Administration route: Oral
    Start date: 2012-06-29

Vorinostat
    Dosage: 230 mg/m2/dose on days 1-4
    Administration route: Oral
    Indication: Medulloblastoma
    Start date: 2012-07-23
    End date: 2012-07-25



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-23

Patient: male

Reactions: Congestive Cardiomyopathy, Systolic Dysfunction

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-06-26
    End date: 2012-06-26

Cyclophosphamide
    Start date: 2012-07-10
    End date: 2012-07-10

Cyclophosphamide
    Start date: 2012-06-08
    End date: 2012-06-08

Cyclophosphamide
    Start date: 2012-06-11
    End date: 2012-06-11

Doxorubicine Actavis
    Start date: 2012-06-26
    End date: 2012-06-29

Doxorubicine Actavis
    Start date: 2012-06-11
    End date: 2012-06-11

Doxorubicine Actavis
    Start date: 2012-07-10
    End date: 2012-07-10

Mabthera
    Start date: 2012-06-11
    End date: 2012-06-11

Mabthera
    Start date: 2012-06-26
    End date: 2012-06-26

Mabthera
    Start date: 2012-06-28
    End date: 2012-06-28

Mabthera
    Start date: 2012-07-05
    End date: 2012-07-05

Mabthera
    Start date: 2012-07-10
    End date: 2012-07-10

Nexium
    Administration route: Oral

Prednisolone
    Administration route: Oral
    Start date: 2012-06-08

Vincristine
    Start date: 2012-06-08
    End date: 2012-06-08

Vincristine
    Start date: 2012-06-11
    End date: 2012-06-11

Vincristine
    Start date: 2012-06-26
    End date: 2012-06-26

Vincristine
    Start date: 2012-07-10
    End date: 2012-07-10

Other drugs received by patient: Etoposide; Cacit D3; Aspirin; Acetaminophen; Prednisone TAB; Acetaminophen W / Codeine; Alendronate Sodium / Cholecalciferol; Previscan; Methotrexate Sodium; Potassium Chloride



Possible Vincristine side effects in 17 year old male

Reported by a physician from Poland on 2012-08-23

Patient: 17 year old male

Reactions: Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Pyrexia, Renal Failure, Neutropenia, Clostridial Infection, Septic Shock

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cefepime

Doxorubicin Hydrochloride
    Indication: Ewing's Sarcoma

Etoposide
    Indication: Ewing's Sarcoma Metastatic

Ifosfamide
    Indication: Ewing's Sarcoma Metastatic

Meropenem

Metronidazole

Netromycin

Vancocin Hydrochloride

Vincristine
    Indication: Ewing's Sarcoma Metastatic

Other drugs received by patient: Fluconazole; Caspofungin Acetate



Possible Vincristine side effects in 49 year old male

Reported by a physician from Norway on 2012-08-23

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Septic Shock, Lung Infiltration

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Baxter 15 000 IE Lyofilisat TIL Injeksjonsv?ske / Infusjonsv?s

Cyclophosphamide

Cyclophosphamide

Doxorubicin Hydrochloride

Doxorubicin Hydrochloride

Etoposide

Etoposide

Prednisolone
    Administration route: Oral

Procarbazine Hydrochloride
    Administration route: Oral

Vincristine



Possible Vincristine side effects in 18 year old female

Reported by a physician from Slovenia on 2012-08-23

Patient: 18 year old female

Reactions: Pulmonary Haemorrhage, Gastrointestinal Haemorrhage, Injection Site Haemorrhage, Sepsis, Shock Haemorrhagic, Acute Respiratory Distress Syndrome, Bone Marrow Failure, Staphylococcal Bacteraemia, Septic Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Heparin

Vincristine
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in male

Reported by a physician from France on 2012-08-22

Patient: male

Reactions: Renal Failure Acute

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-21
    End date: 2012-05-23

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-21
    End date: 2012-05-21

Levoleucovorin Calcium
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-05-21
    End date: 2012-05-26

Mabthera
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-19
    End date: 2012-05-19

Methotrexate Disodium
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-20
    End date: 2012-05-20

Prednisone TAB
    Administration route: Oral
    Indication: Burkitt's Lymphoma
    Start date: 2012-05-20
    End date: 2012-05-25

Vincristine
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-05-20
    End date: 2012-05-26

Other drugs received by patient: Valaciclovir HCL; Lyrica; Bactrim DS; Emend; Allopurinol; Cytarabine; Ondansetron Hydrochloride; Nexium; Calciparine



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from United Kingdom on 2012-08-22

Patient:

Reactions: Cystitis Noninfective

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1222.5 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-05-24
    End date: 2012-08-02

Doxorubicin HCL
    Dosage: 81.5 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-05-24
    End date: 2012-08-02

Prednisolone
    Dosage: 100 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-05-24
    End date: 2012-08-02

Rituximab
    Dosage: 611.75 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-05-24
    End date: 2012-08-02

Velcade
    Dosage: 2.11 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-06-12
    End date: 2012-08-09

Vincristine
    Dosage: 2 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-05-24
    End date: 2012-08-02



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Doxorubicin HCL
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Vincristine side effects in 51 year old male

Reported by a physician from Japan on 2012-08-22

Patient: 51 year old male, weighing 57.7 kg (126.9 pounds)

Reactions: Hypophosphataemia, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Metabolic Acidosis, Hyperphosphataemia, Disseminated Intravascular Coagulation

Adverse event resulted in: death

Drug(s) suspected as cause:
Allopurinol
    Dosage: 300 mg, unk

Allopurinol
    Dosage: 200 mg, unk
    Indication: Tumour Lysis Syndrome

Cyclophosphamide
    Dosage: 1200 mg, unk
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: 80 mg, unk
    Indication: Lymphoma

Methylprednisolone
    Dosage: 250 mg/day
    Indication: Lymphoma

Methylprednisolone
    Dosage: 60 mg/day

Sodium Bicarbonate
    Indication: Metabolic Acidosis

Vincristine
    Dosage: 2 mg, unk
    Indication: Lymphoma



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014